One2Treat

Empowering patients is more than a goal, it’s the future of clinical research. One2Treat's latest publication in the Journal for Clinical Studies explores how the Net Treatment Benefit (NTB) is driving this shift.   • The NTB provides a comprehensive view by integrating multiple clinical outcomes into the treatment assessment, aligning with what patients value most. • Balances multiple clinical outcomes in a single statistical analysis, offering a transparent assessment beyond traditional single endpoint metrics. • Includes patient preferences directly into the analysis, enabling more personalized and meaningful treatment decisions.   The Net Treatment Benefit stands out by allowing to reflect patient priorities and advancing informed decision-making as we move towards incorporating patient preferences into clinical trials. Read the full article: https://lnkd.in/evt8yJPb Thanks to Sébastien Coppe, PhD and Samuel Salvaggio, PhD for writing this great piece 🎉

Our team Sébastien Coppe, PhD and Samuel Salvaggio, PhD being interview by Moe Alsumidaie of The Clinical Trial Vanguard at #SCOPE2024 🤩

This week, Samuel Salvaggio, PhD and Sébastien Coppe, PhD are representing One2Treat at the SCOPE Summit in Barcelona, connecting with industry leaders and gathering insights to drive our vision forward.    Hear what they had to say on Day 1 of the conference!   #SCOPE2024 #PatientEngagement #ClinicalTrials

Thanks to the EORTC - European Organisation for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group for the opportunity to present earlier today at the Autumn Meeting 2024 in Turin, Italy!   Sébastien Coppe, PhD and Pascal Piedbois presented "New endpoints for clinical trials: Net Treatment Benefit" and how this can improve understanding of treatment effects. The Net Treatment Benefit integrates multiple outcomes into a single patient-centric endpoint, offering a multidimensional approach to estimate and report treatment effects. This is especially useful in rare cancer trials, where identifying a single outcome is challenging, and it helps reduce sample sizes.   It was great to exchange insights with fellow researchers and clinicians!   #EORTC #ClinicalTrials #NetTreatmentBenefit #PatientOutcomes

This Thursday, One2Treat’s Samuel Salvaggio, PhD and Jean-Christophe Chiêm, PhD will attend 𝐓𝐡𝐞 𝐒𝐲𝐦𝐩𝐡𝐨𝐧𝐲 𝐨𝐟 𝐔𝐬 𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫 𝐅𝐨𝐫𝐮𝐦 discussing Patient Value in Oncology Research.   The event, supported by the King Baudouin Foundation, gathers a diverse group of stakeholders (patients, patient organizations, carers, healthcare providers, researchers, investors, policymakers, industry, health law…) to engage in a dialogue to explore present and future challenges. The goal? A symphony of collaboration where the voice of every stakeholder is heard. 🎵 Are you also attending this event at La Tricoterie? Get in touch!

🚀 Less than two weeks until SCOPE Europe 2024 in Barcelona!   We’re looking forward to connecting with professionals from across the industry. With discussions focused on clinical trial innovation, it’s a great opportunity to collaborate and share insights on advancing research.   One2Treat is excited to engage with peers and explore how we can work together to drive your clinical trials forward.   Let’s make the most of this event—drop a message to Sébastien Coppe, PhD or Samuel Salvaggio, PhD if you’ll be in Barcelona!   #SCOPEEU2024 #clinicaltrials #patientfocused

𝐍𝐞𝐭 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐁𝐞𝐧𝐞𝐟𝐢𝐭 (𝐍𝐓𝐁): 𝐀 𝐏𝐚𝐭𝐢𝐞𝐧𝐭-𝐅𝐨𝐜𝐮𝐬𝐞𝐝 𝐀𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭 𝐨𝐟 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬 The NTB estimates treatment effects by combining multiple outcomes into a single metric, enabling a comprehensive understanding of their impact. 𝐖𝐡𝐲 𝐝𝐨𝐞𝐬 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫?  • Bridge the gap between patient experiences and statistic assessments  • Leverage all clinically relevant information into a single assessment  • Pave the way from trial design to market access Discover how One2Treat’s solutions are facilitating more informed decision-making.   💡 Want to know more? Let's connect! #ClinicalTrials #NetTreatmentBenefit #PatientFocused

The 7th Annual New England Rare Disease Statistics (NERDS) Workshop 2024 kicks off today in Boston, and we’re delighted to be part of it!   Tomorrow, One2Treat founder Marc Buyse will take the stage to share how Generalized Pairwise Comparisons (GPC) can boost statistical power while keeping patient needs front and center—an approach that’s especially critical in rare disease research. GPC allows us to assess treatment outcomes in a more meaningful way, prioritizing what truly matters for patients. Thanks to NEW ENGLAND STATISTICAL SOCIETY for organizing the event 🙏   #NERDS #Raredisease #Patientfocus

𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥 𝐃𝐞𝐬𝐢𝐠𝐧 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭   Outsourcing-Pharma recently interviewed Samuel Salvaggio, PhD, to discuss how One2Treat is transforming clinical trials with a groundbreaking patient-focused approach. By integrating multiple patient-relevant outcomes into a single primary endpoint, One2Treat can significantly reduce trial sample sizes.   💡 Key Takeaways:   • Patient-Focused Design: Engaging patients already from the trial design phase ensures a meaningful evaluation of efficacy, safety, and quality of life. • Data Utilization: Leveraging more detailed patient data results in greater clinical relevance and minimizes the need for larger sample sizes. • Regulatory Support: Regulatory bodies are increasingly backing innovative methodologies that utilize patient-reported outcomes in clinical trial frameworks.   Discover how One2Treat is setting new standards in clinical research! 🔗 Read the full article here: https://lnkd.in/ezD5N9nv #PDFF #ClinicalTrials #patientfocused

Next week, One2Treat's founder Marc Buyse will be presenting at the 7th Annual New England Rare Disease Statistics (NERDS) Workshop 2024, organized by the NEW ENGLAND STATISTICAL SOCIETY, happening in Boston 10-11th of October. Marc was invited to discuss how the use of Generalized Pairwise Comparisons (GPC) can increase statistical power and patient-centricity, especially valuable for rare disease drug development. By prioritizing outcomes based on clinical relevance, GPC can provide a more comprehensive assessment of treatment effects. We look forward to an insightful exchange of expertise, ideas, and innovations!